Jul. 28 at 1:20 PM
📊
$GOVX Q2 Snapshot: A much smaller loss than Wall Street expected
GeoVax reported second-quarter results with no product revenue, as expected for a clinical-stage biotech, while delivering a significantly narrower loss than analysts anticipated.
Key highlights:
• EPS: Loss of
$0.97, beating the Zacks Consensus Estimate of a
$2.16 loss
• Revenue: No product sales were reported, as GeoVax currently has no marketed products
• Management continued advancing GEO-MVA toward a planned pivotal immunobridging study while progressing its oncology program, Gedeptin.
See what Wall Street's price target implies for
$GOVX from here. 👇
https://www.zacks.com/stock/quote/GOVX/detailed-earning-estimates?cid=sm-stocktwits-0-detailed_estimates-teaser-38993&ADID=SYND_STOCKTWITS_TWEET_0_DETAILEDESTIMATES_TEASER_38993
